Evidence map›Paper›PMID 40697975›Full record

ReviewBrain, behavior, & immunity - health2025

Exploring GPR120/FFAR4 pharmacology: Unveiling novel therapeutic avenues through molecular signaling pathways for Alzheimer's disease intervention.

Priyadharshini Gogu, Jayhind Bharti, Jagat Pal Yadav, Maria Grishina, Amita Verma, Vikas Kumar, Ankit Kumar Singh, Akash Verma, Pradeep Kumar, Habibullah Khalilullah and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Priyadharshini GoguLaboratory of Drug Discovery, School of Pharmacy, GITAM (Deemed to be University), 502239, India.
Jayhind BhartiLaboratory of Drug Discovery, School of Pharmacy, GITAM (Deemed to be University), 502239, India.
Jagat Pal YadavBioorganic and Medicinal Chemistry Research Laboratory, School of Pharmacy, Sam Higginbottam Institute of Agriculture, Technology and Sciences, 211007, India.
Maria GrishinaLaboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, 226026, Russia.
Amita VermaBioorganic and Medicinal Chemistry Research Laboratory, School of Pharmacy, Sam Higginbottam Institute of Agriculture, Technology and Sciences, 211007, India.
Vikas KumarBioorganic and Medicinal Chemistry Research Laboratory, School of Pharmacy, Sam Higginbottam Institute of Agriculture, Technology and Sciences, 211007, India.
Ankit Kumar SinghBioorganic and Medicinal Chemistry Research Laboratory, School of Pharmacy, Sam Higginbottam Institute of Agriculture, Technology and Sciences, 211007, India.
Akash VermaTeerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, 244001, U.P., India.
Pradeep KumarDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India.
Habibullah KhalilullahDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Saudi Arabia.
Mariusz JaremkoSmart-Health Initiative and Red Sea Research Center, Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia.
Abdul-Hamid EmwasCore Labs, King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia.
Ashish R DwivediLaboratory of Drug Discovery, School of Pharmacy, GITAM (Deemed to be University), 502239, India.
Prateek PathakLaboratory of Drug Discovery, School of Pharmacy, GITAM (Deemed to be University), 502239, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G-protein-coupled receptors (GPCRs) are a major class of membrane proteins involved in numerous physiological and pathological processes. Among them, free fatty acid receptor 4 (FFAR4/GPR120), activated by long-chain free fatty acids, has shown anti-inflammatory effects and is expressed in the brain-implicating its role in neurodegenerative diseases like Alzheimer's disease (AD). AD is characterized by brain atrophy, cognitive decline, and neuroinflammation, involving complex signaling networks. This review explores the pharmacological relevance of GPR120/FFAR4 in AD, focusing on its involvement in neuroinflammatory, amyloidogenic, and intracellular signaling cascades. Targeting GPR120 may help modulate chronic inflammation and amyloid-β accumulation. Additionally, activation of nuclear receptors and regulation of pathways such as MAPK, NLRP3, PPARs, and cAMP have shown promise in mitigating AD pathology. Despite the complexity of brain signaling, GPR120 emerges as a compelling multitarget therapeutic receptor. These insights provide a foundation for developing novel anti-inflammatory strategies in AD treatment.

Indexed as

GPCRMAPKNeuroinflammationNeuroprotectionNLRP3PPARsTherapeutic targets

Identifiers

PMID40697975
PMCPMC12281026

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.